[Iatrogenic botulism in therapeutic use of botulinum toxin]

Ugeskr Laeger. 2022 Feb 14;184(7):V07210574.
[Article in Danish]

Abstract

The review summarises the current knowledge of the treatment of iatrogenic botulinum toxin overdose. The symptoms may be diffuse, and suspicion should be raised based on time of symptom appearance relative to the time of exposure. Iatrogenic botulism may appear if the maximum recommended total dose of botulinum toxin has been exceeded and if the drug is spread locally from the site of injection or is redistributed to the systemic circulation. The adverse drug reactions frequency is possibly underreported. Fast initiation of the available antidote may be needed. The guideline provided on treatment of iatrogenic botulism is developed from non-iatrogenic botulism.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A* / adverse effects
  • Botulism* / chemically induced
  • Botulism* / diagnosis
  • Botulism* / drug therapy
  • Humans
  • Iatrogenic Disease

Substances

  • Botulinum Toxins, Type A